The CSU indication is the seventh disease driven in part by underlying type 2 inflammation in which Dupixent has received approval.

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and ...

The FDA has approved Dupixent for chronic spontaneous urticaria in patients 12 and older unresponsive to antihistamines, ...

Chris Brookes-Smith could have died from eating peanuts - but taking part in a clinical trial has changed his life.

ADULTS can beat peanut allergies by eating tiny amounts with medical help and building up a tolerance, an NHS study suggests.

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adults and adolescents with ...

The FDA approves SNY and REGN's Dupixent for treating chronic spontaneous urticaria, marking the seventh approved indication of the drug.

Sanofi and Regeneron's fully human monoclonal antibody Dupixent (dupilumab) has gained approval from the US Food and Drug ...